↓ Skip to main content

A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis

Overview of attention for article published in Investigational New Drugs, February 2009
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#3 of 1,256)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

twitter
6 X users
facebook
529 Facebook pages
googleplus
26 Google+ users

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
31 Mendeley
Title
A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis
Published in
Investigational New Drugs, February 2009
DOI 10.1007/s10637-009-9221-0
Pubmed ID
Authors

Rosanna Cozzolino, Gaetano Calì, Maurizio Bifulco, Paolo Laccetti

Abstract

The active components of Cannabis sativa and their derivatives produce a wide spectrum of effects, some of which may have clinical application. The discovery of specific cannabinoid receptors and a family of endogenous ligands of those receptors has attracted much attention to cannabinoids as agents capable of controlling the decision of cells to survive or die. We analysed the effects exerted by 2-methyl-2'-F-anandamide (Met-F-AEA), a metabolically stable analogue of anandamide, and observed a growth inhibition in cell lines derived from thyroid carcinomas. Growth inhibition was associated with a high level of CB1 receptor expression, suggesting that the cytotoxic effect is due to interaction with the CB1 receptor. This phenomenon was associated with activation of the protein, p53, an increased apoptotic rate, and expression of p21(CIP1/WAF1). This study provides new insights into the mechanism of Met-F-AEA action, and could have significance in providing a basis for the management of thyroid carcinoma.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
United States 1 3%
Unknown 29 94%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 16%
Researcher 5 16%
Student > Ph. D. Student 4 13%
Student > Master 3 10%
Other 3 10%
Other 3 10%
Unknown 8 26%
Readers by discipline Count As %
Agricultural and Biological Sciences 6 19%
Medicine and Dentistry 6 19%
Biochemistry, Genetics and Molecular Biology 4 13%
Social Sciences 3 10%
Nursing and Health Professions 2 6%
Other 2 6%
Unknown 8 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 162. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 October 2023.
All research outputs
#248,015
of 25,176,926 outputs
Outputs from Investigational New Drugs
#3
of 1,256 outputs
Outputs of similar age
#766
of 187,173 outputs
Outputs of similar age from Investigational New Drugs
#1
of 7 outputs
Altmetric has tracked 25,176,926 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,256 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,173 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them